Articles tagged with Drug Therapy
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Research reveals associations between antiseizure drugs and neurodevelopmental disorders in children, with valproate and zonisamide linked to increased risks. The study highlights the need for continued monitoring of new antiseizure drugs and further evaluation of their safety during pregnancy.
Research shows that bacteria harbor resistance genes may respond differently to antibiotics under non-standard conditions. This affects treatment efficacy and contributes to understanding antimicrobial resistance development and spread. Understanding these variations is crucial to combat global public health threats.
New prescriptions for stimulants among adults with ADHD more than doubled since the COVID-19 pandemic, with the largest increases among younger adults. The trend is driven by improved recognition and treatment of ADHD in adulthood, as well as increased access to care and virtual health services.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new medication called zorevunersen has been found to reduce seizures in children with Dravet syndrome by up to 91%, improving their quality of life and behavior. The study, led by University College London and Great Ormond Street Hospital, also showed the potential to reduce the impact of the condition on mental processes.
Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.
A study by São Paulo State University found that an iron-based compound eliminated lung infection in mice after 30 days of treatment. The researchers developed lipid nanoparticles to improve stability and duration of action, outperforming standard antibiotics in eliminating the bacterial load.
The study found that opioids provide only small, time-limited pain relief for certain pain conditions, such as stomach pain and dental surgery. Regular use of opioids comes with a risk of harm, including dependence and overdose.
A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...
A study published in JAMA Network Open found that early hydrocortisone treatment increases the chance of surviving without lung disease for extremely premature babies. The treatment is safe and does not increase serious side effects.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
Researchers at the University of Iowa Health Care identified acetazolamide as a potential target for preventing opioid use disorder relapse. The study found that blocking the activity of brain enzyme carbonic anhydrase 4 boosted acid-sensing ion channels, reducing drug-seeking behavior and relapse in mice.
Researchers found that brexpiprazole significantly improved information processing speed without worsening psychiatric symptoms in patients with schizophrenia. Cognitive dysfunction is a persistent challenge, affecting daily functioning and social participation.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Researchers discovered that collaborative care programs improve quality of life, reduce costs, and alleviate caregiver burden for dementia patients. Adding lecanemab to treatment increased healthcare costs but was offset by the savings from collaborative care.
A new study found semaglutide to be an effective treatment for preventing secondary cardiovascular disease in US adults. The medication meets conventional thresholds when used alone, but its cost-effectiveness is improved with combination therapy.
A new study offers hope that kidney transplant patients may one day have a more effective treatment regimen. The Phase 2 pilot study showed improved kidney functioning in all patients who completed the study, with no patients experiencing rejection due to antibodies produced by the immune system.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
The study found that metformin reduces the risk of developing Long COVID by approximately one case for every 50 cases of acute SARS-CoV-2 treated with 14 days of metformin. Metformin can be used alone or combined with other treatments to prevent Long COVID in most adults.
A new study led by Dr. Chu Chen suggests that combining THC with celecoxib may improve cognition and reduce Alzheimer's-related brain pathology in mice. The combination produced better outcomes than low-dose THC alone, including improved learning and memory performance and reduced markers of neuroinflammation.
The ISSCR is hosting a summit on access and affordability in cell and gene therapies to explore pricing, manufacturing, regulation, and reimbursement strategies. Experts will examine key barriers and emerging solutions across the access landscape.
The Japanese version of the rPATD questionnaire has been validated to assess attitudes towards medication reductions among older adults and their caregivers in Japan. The tool is reliable, valid, and easily understood, facilitating shared decision-making between healthcare providers and patients.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers analyzed medical records of 1,269 elderly patients with advanced cancer to find that over 70% were prescribed potentially inappropriate medications (PIMs), which declined closer to death. PIM discontinuation was more common among female patients, those with polypharmacy, and palliative care unit admissions.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
A new study by the University of Texas at Arlington examines how updated CDC guidelines can help nurse practitioners reduce opioid misuse and protect patients. The guidelines emphasize individualized care, clinical judgment, and ongoing reassessment to ensure safe prescribing practices.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
The FDA's regulation of mifepristone involves characterizing its decision-making process and rationale for key components. The agency's approach has evolved over time, with notable changes to its regulatory framework.
Researchers have made a groundbreaking discovery about how bacteria swim upstream to cause infections, pointing to new designs for biomedical devices that can prevent contamination. The study found that wider channels with faster counterflows are more prone to invasion, but sharp corner designs can inhibit bacterial growth.
A new study found that 4.9 million adults in Great Britain have recently used a drug to support weight loss or were interested in using one in the near future. The usage far exceeds NHS England's initial goal of prescribing these drugs to 220,000 people over three years.
Researchers at the University of Illinois discovered that propofol, a common anesthetic agent, can improve cognitive function after surgery in older individuals. Additionally, intranasal insulin was found to mitigate age-related memory impairment by modulating neuroinflammatory mechanisms.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Acute sepsis alters fluid kinetics and creates a 'third space' resistant to adrenergic modulation, leading to maldistribution of crystalloid fluid. Vasoactive drugs have limited effect on fluid distribution in septic sheep compared to healthy animals.
Researchers at UVA Health System discover how traumatic brain injury increases Alzheimer's risk and find a potential prevention strategy using a hollowed-out virus to deliver repair supplies. The approach could help limit neurodegeneration and potentially prevent other neurological diseases.
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
Combocat integrates miniaturized drug dispensing with machine learning to efficiently uncover promising drug combinations. The platform's capabilities were published in Nature Communications, demonstrating its potential for scaling up drug combination screening.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
A new study found that annual ADHD prescription rates increased by 157 percent in Ontario from 2015 to 2023, with significant increases in females and younger age groups. The authors suggest a potential rise in true cases of ADHD, improved diagnosis, or misdiagnosis as contributing factors.
Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.
Scientists have developed an experimental drug called TY1 that repairs DNA damage and promotes healing in damaged tissue. The breakthrough could lead to new treatments for heart attacks, autoimmune diseases, and other conditions.
A growing trend of antipsychotic medication prescription increases in older U.S. adults, with long-term care pharmacies being a primary source. Non-psychiatrist prescribers contribute to the trend, highlighting concerns over medication accessibility and oversight.
Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.
Researchers tracked 120 older veterans taking gabapentinoids and loop diuretics, finding that only 4 doctors correctly identified the gabapentinoids as the cause of leg swelling. The study highlights the dangers of 'prescribing cascades' and emphasizes the need for regular monitoring and alternative treatment options.
A new study found that long-term antidepressant use has increased by nearly 20% among young people aged 10-24, raising concerns about potential overprescribing. The study also found no meaningful improvement in efforts to wean patients off antidepressants, highlighting the need for a stronger framework for safely tapering medications.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack by delivering interleukin-4 directly to damaged heart tissue. The patch uses a microneedle system to promote repair and improve heart function without affecting the rest of the body.
Researchers at Florida Atlantic University have discovered a potential new treatment for Alzheimer's disease by targeting muscle protein Cathepsin B. The study found that increasing Ctsb in muscle tissue may offer protection against the effects of AD and promote brain cell growth, restoring protein balance and rebalancing brain activity.
A study by Aston University academics found that while access to antiseizure medication is expanding globally, it's not always prescribed safely. Valproate, widely used, poses significant risks during pregnancy, including birth defects and neurodevelopmental problems.
A new compound MCH11, a monoacylglycerol lipase inhibitor, shows promising effects in reducing alcohol consumption and motivation to drink in mice. The molecule exhibits anxiolytic and antidepressant properties with sex-dependent efficacy, correcting genetic alterations associated with alcohol use disorder.
Researchers at UVA School of Medicine found that the breakdown of protective brain structures called perineuronal nets leads to social memory loss in Alzheimer's patients. Preventing the degradation of these nets may lead to new treatments to prevent or delay the disease.
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
Researchers from Intermountain Health have found that GLP-1 receptor agonists do not increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides. Patients taking these medications had a four times lower risk of developing pancreatitis compared to those not on the medication.
A new AI model uses machine learning to predict drug toxicity in humans by identifying biological differences between cells, mice, and humans. The model improved predictive power over existing state-of-the-art models and demonstrated practicality in predicting market withdrawal due to toxicity.
West Virginia University researchers are working with local partners to stop drug use in youth before it starts. They will expand an existing pilot project to encompass 140 schools in 36 rural counties, tailored to individual community needs.